Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Tate & Lyle says CP Kelco integration on track, results in line

(Sharecast News) - Food ingredients group Tate & Lyle said it expects to deliver full-year results in line with guidance, with the recently acquired CP Kelco division delivering margin improvements ahead of expectations. Tate & Lyle, which in November completed a deal to merger with pectin, gums and ingredients firm CP Kelco, said the integration of the two companies is on track, with the enlarged group operating as a combined business from the start of April.

When excluding CP Kelco, revenues for the 12 months to 31 March were down 5% on the previous year while EBITDA grew by 4%.

CP Kelco is said to have traded "well" with an increase in EBITDA margin of more than 90 basis points for the full financial year, ahead of the company's acquisition plan which "further reinforces our confidence in its phased margin recovery", it said.

The company said it was confident in its targeted run-rate cost synergies of $50m by the end of the financial year ending 2027, with more than 50% of these to be delivered in the current financial year.

"Notwithstanding the uncertain macroeconomic environment, we are confident in the medium-term growth potential of the business we have created and are focused on delivering the benefits of the combination with CP Kelco and accelerating topline growth," said chief executive Nick Hampton.

"Our confidence in the growth opportunity ahead has been strengthened by the positive engagement we are seeing from customers in both our expanded portfolio and capabilities."

Shares were up 3.2%at 519.76p by 0820 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.